چهارشنبه 3 تیر 1405
[Archive]
پذیرفته شده و در حال انتشار
برگشت به فهرست مقالات |
برگشت به فهرست نسخه ها
Ethics code: IR.MAZUMS.REC.1402.17969.
چکیده: (6 مشاهده)
Background and Objective: Currently, combination drug therapy has emerged as a promising strategy in cancer treatment, as the simultaneous administration of two drugs can enhance therapeutic efficacy and overcome drug resistance. This study aimed to investigate the combined effects of colchicine: microtubule-disrupting alkaloid and melatonin: antioxidant and oncostatic properties on cell viability and expression of apoptosis-related genes (BAX and BCL2) in MCF-7 human breast cancer cell line.
Methods: MCF-7 cells were cultured under standard conditions and treated with colchicine, melatonin, or their combination for 24, 48, and 72 hours. Cell viability was determined using MTT assay and BAX and BCL2 gene expression were quantified by reverse transcription polymerase chain reaction.
Results: The MTT assay at 48 hours revealed IC50 values of 150 µg/ml for colchicine and 371 µg/ml for melatonin. Combination treatment with colchicine (>25 µg/ml) and a fixed concentration of melatonin (150 µg/ml) resulted in a 50% reduction in cell viability (P<0.01). Gene expression analysis showed that colchicine (75 µg/ml), melatonin (250 µg/ml), and their combination (colchicine: 25 µg/ml; melatonin: 150 µg/ml) significantly increased BAX expression and decreased BCL2 expression compared with the control group (P<0.05).
Conclusion: Co-treatment with colchicine and melatonin significantly reduced MCF-7 cell viability and regulated apoptosis-related genes (BAX and BCL2), indicating a synergistic effect. These findings suggest that this combination may represent a promising therapeutic strategy for breast cancer. Further in vivo and clinical studies are required to confirm these findings.
Methods: MCF-7 cells were cultured under standard conditions and treated with colchicine, melatonin, or their combination for 24, 48, and 72 hours. Cell viability was determined using MTT assay and BAX and BCL2 gene expression were quantified by reverse transcription polymerase chain reaction.
Results: The MTT assay at 48 hours revealed IC50 values of 150 µg/ml for colchicine and 371 µg/ml for melatonin. Combination treatment with colchicine (>25 µg/ml) and a fixed concentration of melatonin (150 µg/ml) resulted in a 50% reduction in cell viability (P<0.01). Gene expression analysis showed that colchicine (75 µg/ml), melatonin (250 µg/ml), and their combination (colchicine: 25 µg/ml; melatonin: 150 µg/ml) significantly increased BAX expression and decreased BCL2 expression compared with the control group (P<0.05).
Conclusion: Co-treatment with colchicine and melatonin significantly reduced MCF-7 cell viability and regulated apoptosis-related genes (BAX and BCL2), indicating a synergistic effect. These findings suggest that this combination may represent a promising therapeutic strategy for breast cancer. Further in vivo and clinical studies are required to confirm these findings.
| بازنشر اطلاعات | |
 |
این مقاله تحت شرایط Creative Commons Attribution-NonCommercial 4.0 International License قابل بازنشر است. |
